Cargando…

Disrupted balance of T cells under natalizumab treatment in multiple sclerosis

OBJECTIVE: To compare effects of natalizumab on inflammatory and regulatory T cells with regard to expression of α4-integrin (CD49d). METHODS: Twenty-seven natalizumab-naive and 8 natalizumab-treated patients with multiple sclerosis (MS), 7 patients with neuromyelitis optica (NMO) or NMO spectrum di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, Kimitoshi, Nakamura, Masakazu, Sato, Wakiro, Okamoto, Tomoko, Araki, Manabu, Lin, Youwei, Murata, Miho, Takahashi, Ryosuke, Yamamura, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784802/ https://www.ncbi.nlm.nih.gov/pubmed/27006971 http://dx.doi.org/10.1212/NXI.0000000000000210

Ejemplares similares

Normal brain imaging accompanies neuroimmunologically justified, autoimmune encephalomyelitis
por: Takewaki, Daiki, et al.
Publicado: (2018)

Th1 ‐ CD11c (+) B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2021)

First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis
por: Sato, Wakiro, et al.
Publicado: (2023)

Ratio of lymphocyte to monocyte area under the curve as a novel predictive factor for severe infection in multiple sclerosis
por: Takahashi, Junichiro, et al.
Publicado: (2023)

Exploring the Potential of the Corpus Callosum Area as a Predictive Marker for Impaired Information Processing in Multiple Sclerosis
por: Akaike, Shun, et al.
Publicado: (2023)

Application of immunotherapy for neurological manifestations in hypermobile Ehlers–Danlos syndrome
por: Araki, Manabu, et al.
Publicado: (2018)

Involvement of cytotoxic Eomes-expressing CD4(+) T cells in secondary progressive multiple sclerosis
por: Raveney, Ben J. E., et al.
Publicado: (2021)

Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2018)

Resident Memory-like CD8(+) T Cells Are Involved in Chronic Inflammatory and Neurodegenerative Diseases in the CNS
por: Kimura, Kimitoshi, et al.
Publicado: (2023)

Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder
por: Matsuoka, Takako, et al.
Publicado: (2023)

Gut microbiota-dependent CCR9(+)CD4(+) T cells are altered in secondary progressive multiple sclerosis
por: Kadowaki, Atsushi, et al.
Publicado: (2019)

The Role for Exosomal microRNAs in Disruption of Regulatory T Cell Homeostasis in Multiple Sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2018)

Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation
por: Raveney, Ben J. E., et al.
Publicado: (2015)

Alterations of the gut ecological and functional microenvironment in different stages of multiple sclerosis
por: Takewaki, Daiki, et al.
Publicado: (2020)

Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
por: Araki, Manabu, et al.
Publicado: (2014)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

A structural MRI study of cholinergic pathways and cognition in multiple sclerosis
por: Kimura, Yukio, et al.
Publicado: (2017)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters
por: Miyake, Sachiko, et al.
Publicado: (2015)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
por: Araki, Manabu, et al.
Publicado: (2012)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
por: Maier, Smaranda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5q1al62b087kb4v5v8plfg9o7g